论文部分内容阅读
目的:研究肺癌脑转移患者应用靶向治疗联合放化疗同步治疗的临床疗效及安全性。方法:选取我院收治的肺癌脑转移患者74例,采取数字随机法分成观察组和对照组,对照组采取全脑放化疗同步治疗,观察组在对照组基础上,采取靶向治疗,比较两组临床疗效及安全性。结果:观察组总有效率94.59%,对照组总有效率81.08%,观察组患者近期疗效总有效率高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率51.35%,对照组不良反应发生率59.46%,两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:肺癌脑转移患者应用靶向治疗联合放化疗同步治疗的临床疗效显著,且不会增加不良反应发生率,是优秀的治疗方法之一。
Objective: To study the clinical efficacy and safety of targeted therapy and concurrent chemoradiotherapy in patients with brain metastasis of lung cancer. Methods: Totally 74 patients with brain metastases of lung cancer admitted to our hospital were divided into observation group and control group by digital random method. The control group was treated with concurrent whole brain radiochemotherapy. The observation group was treated with targeted therapy on the basis of control group. Group clinical efficacy and safety. Results: The total effective rate was 94.59% in the observation group and 81.08% in the control group. The total effective rate in the observation group was higher than that in the control group (P <0.05). The incidence of adverse reactions in the observation group was 51.35%, and the incidence of adverse reactions in the control group was 59.46%. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The clinical curative effect of targeted therapy combined with chemoradiotherapy in patients with brain metastasis of lung cancer is significant, and will not increase the incidence of adverse reactions, which is one of the excellent treatment methods.